These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 24919951)

  • 1. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
    Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
    Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.
    Bui QT; Im JH; Jeong SB; Kim YM; Lim SC; Kim B; Kang KW
    Cancer Lett; 2017 Apr; 390():115-125. PubMed ID: 28108315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.
    Simões BM; O'Brien CS; Eyre R; Silva A; Yu L; Sarmiento-Castro A; Alférez DG; Spence K; Santiago-Gómez A; Chemi F; Acar A; Gandhi A; Howell A; Brennan K; Rydén L; Catalano S; Andó S; Gee J; Ucar A; Sims AH; Marangoni E; Farnie G; Landberg G; Howell SJ; Clarke RB
    Cell Rep; 2015 Sep; 12(12):1968-77. PubMed ID: 26387946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological and clinical implications of nicastrin expression in invasive breast cancer.
    Filipović A; Gronau JH; Green AR; Wang J; Vallath S; Shao D; Rasul S; Ellis IO; Yagüe E; Sturge J; Coombes RC
    Breast Cancer Res Treat; 2011 Jan; 125(1):43-53. PubMed ID: 20224929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
    Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
    BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.
    Clementz AG; Rogowski A; Pandya K; Miele L; Osipo C
    Breast Cancer Res; 2011 Jun; 13(3):R63. PubMed ID: 21679465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo.
    Lombardo Y; Filipović A; Molyneux G; Periyasamy M; Giamas G; Hu Y; Trivedi PS; Wang J; Yagüe E; Michel L; Coombes RC
    Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16558-63. PubMed ID: 23012411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
    Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
    BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches.
    Rizzo P; Miao H; D'Souza G; Osipo C; Song LL; Yun J; Zhao H; Mascarenhas J; Wyatt D; Antico G; Hao L; Yao K; Rajan P; Hicks C; Siziopikou K; Selvaggi S; Bashir A; Bhandari D; Marchese A; Lendahl U; Qin JZ; Tonetti DA; Albain K; Nickoloff BJ; Miele L
    Cancer Res; 2008 Jul; 68(13):5226-35. PubMed ID: 18593923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells.
    Lee J; Sehrawat A; Singh SV
    Breast Cancer Res Treat; 2012 Nov; 136(1):45-56. PubMed ID: 22965833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation.
    Liang YK; Zeng D; Xiao YS; Wu Y; Ouyang YX; Chen M; Li YC; Lin HY; Wei XL; Zhang YQ; Kruyt FA; Zhang GJ
    Cancer Lett; 2017 Feb; 386():65-76. PubMed ID: 27838413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.
    Wang Z; Li Y; Kong D; Banerjee S; Ahmad A; Azmi AS; Ali S; Abbruzzese JL; Gallick GE; Sarkar FH
    Cancer Res; 2009 Mar; 69(6):2400-7. PubMed ID: 19276344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097.
    Wang L; Dai G; Yang J; Wu W; Zhang W
    Med Sci Monit; 2018 Jun; 24():4046-4053. PubMed ID: 29899322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation.
    Faronato M; Nguyen VT; Patten DK; Lombardo Y; Steel JH; Patel N; Woodley L; Shousha S; Pruneri G; Coombes RC; Magnani L
    Oncotarget; 2015 Sep; 6(26):22467-79. PubMed ID: 26093085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential patterns of NOTCH1-4 receptor expression are markers of glioma cell differentiation.
    Dell'albani P; Rodolico M; Pellitteri R; Tricarichi E; Torrisi SA; D'Antoni S; Zappia M; Albanese V; Caltabiano R; Platania N; Aronica E; Catania MV
    Neuro Oncol; 2014 Jan; 16(2):204-16. PubMed ID: 24305720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
    Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
    J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
    Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.